| |
Redefine what it means to be inspection-ready with Premier’s Inspection Readiness Program. This four-phase plan will arm you with the knowledge, skills, and confidence to successfully host health authority inspections. Get started with our brochure. 
|
|
Today’s Big NewsOct 23, 2024 |
|
The deal will help Jubilant Biosys expand its footprints in Europe for drug discovery and pre-clinical offerings in areas like biologics and ADC on top of existing integrated drug discovery services & CDMO from India. .png)
|
|
| By Nick Paul Taylor Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate disappointed in phase 2, disclosed the setback as part of a wider pullback from prospects that fell short of the bar for further development. |
|
|
|
By Darren Incorvaia Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma. |
By Nick Paul Taylor Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary endpoints, prompting investors to wipe 60% off the biotech’s share price. |
Sponsored by Travere Therapeutics When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced. |
|
- 45 markers for cytokine signaling/inflammation
- Trust RBM for Olink, Luminex & Simoa immunoassays
|
|
By Nick Paul Taylor Sangamo Therapeutics has identified a shortcut to market for its Fabry disease candidate, aligning with the FDA on a pathway that could slash three years from the time to market and free it from the need to run an additional registrational study. Shares in Sangamo jumped 33% to $1.22 in the wake of the news. |
Sponsored by TriNetX, Inc. Now’s the time to rethink clinical trials with real-world data (RWD). Discover strategies to optimize your protocols and site selection. |
By James Waldron Alpha-9 Oncology has raised a $175M series C to fund its clinical-stage radiopharma drugs, although the exact details of the biotech’s pipeline remain hazy for now. |
By James Waldron Eye drug maker Ocuphire is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity. |
By Darren Incorvaia GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune-related respiratory and kidney diseases, the London-based pharma giant announced in an Oct. 21 release. |
By Fraiser Kansteiner Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court. That said, Regeneron is appealing the decision and stressed that it continues to believe Amgen's copycat infringes multiple Eylea patents. |
By Kevin Dunleavy Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. The layoffs come three months after the company axed 150 positions in Sanford following a high-profile phase 3 trial failure for its Duchenne muscular dystrophy gene therapy candidate. The company said that the new wave of layoffs are related to the trial results. |
By Noah Tong Recent price transparency regulations have caused prices to converge for outpatient services but led to more discrepancy for inpatient services, according to findings from Turquoise Health. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
